Safety Results Through Week 52 From the Randomized Controlled Phase 3 VERIFY Study. Oral presentation at: American Society of Hematology Annual Meeting, December 6, 2025. Orlando, FL. Presentation ID 81.

Kuykendall A, et al. Rusfertide or Placebo Plus Current Standard of Care Therapy for Polycythemia Vera: Durability of Response and Safety Results Through Week 52 From the Randomized Controlled Phase 3 VERIFY Study. Abstract accepted for oral presentation at: American Society of Hematology 2025 Annual Meeting. Orlando, FL. Abstract ID 81.

Pemmaraju N, et al. Long-term rusfertide treatment in polycythemia vera: Initial results from the Phase 2 THRIVE extension study. Abstract accepted for poster presentation at: American Society of Hematology 2025 Annual Meeting. Orlando, FL. Abstract ID 3810.








Contacts


Protagonist Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesc
=*=*=*=*=*=
当前为第22/23页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页